An Overview of Mesenchymal Stem Cell-based Therapy Mediated by Noncoding RNAs in the Treatment of Neurodegenerative Diseases

Stem Cell Rev Rep. 2022 Feb;18(2):457-473. doi: 10.1007/s12015-021-10206-x. Epub 2021 Aug 4.

Abstract

Mesenchymal stem cells (MSCs) have become a promising tool for neurorestorative therapy of neurodegenerative diseases (NDDs), which are mainly characterized by the progressive and irreversible loss of neuronal structure and function in the central or peripheral nervous system. Recently, studies have reported that genetic manipulation mediated by noncoding RNAs (ncRNAs) can increase survival and neural regeneration of transplanted MSCs, offering a new strategy for clinical translation. In this review, we summarize the potential role and regulatory mechanism of two major types of ncRNAs, including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), during the neurogenesis of MSCs with gene expression profile analyses. We also overview the realization of MSC-based therapy mediated by ncRNAs in the treatment of spinal cord injury, stroke, Alzheimer's disease and peripheral nerve injury. It is expected that ncRNAs will become promising therapeutic targets for NDD on stem cells, while the underlying mechanisms require further exploration.

Keywords: Long noncoding RNA; Mesenchymal stem cells; MicroRNA; Nerve regeneration; Neurodegenerative diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Mesenchymal Stem Cells*
  • MicroRNAs* / genetics
  • MicroRNAs* / metabolism
  • Neurodegenerative Diseases* / genetics
  • Neurodegenerative Diseases* / therapy
  • RNA, Long Noncoding* / genetics
  • RNA, Long Noncoding* / metabolism
  • RNA, Untranslated / genetics

Substances

  • MicroRNAs
  • RNA, Long Noncoding
  • RNA, Untranslated